This blood pressure drug may treat liver disease by reducing inflammation

Credit: Unsplash+

Chronic liver damage is a serious condition that can lead to severe complications. When the liver is damaged over time, scar tissue forms, making it harder for blood to flow through the organ.

This can cause a condition called portal hypertension, where blood pressure rises in the portal vein, a major blood vessel carrying blood from the digestive organs to the liver.

Portal hypertension can result in dangerous complications, including swollen veins (varices) that may burst and cause severe bleeding, fluid buildup in the abdomen (ascites), and brain dysfunction due to toxin buildup (hepatic encephalopathy).

A recent study conducted by MedUni Vienna has discovered a promising additional benefit of a common medication for high blood pressure, known as beta-blockers, in patients with advanced liver disease.

Beta-blockers have long been used to manage portal hypertension, but they may also help reduce inflammation throughout the body—a key factor in the progression of liver disease.

The study examined patients with cirrhosis, an advanced stage of liver damage marked by severe scarring. Researchers identified markers of systemic inflammation, which refers to widespread inflammation affecting the entire body, before and during beta-blocker treatment.

They found that patients with more advanced cirrhosis were more likely to experience systemic inflammation but also benefited more significantly from the anti-inflammatory effects of beta-blockers.

Patients undergoing beta-blocker therapy showed reduced levels of inflammatory markers, such as white blood cell counts, which are often elevated during systemic inflammation. This reduction in inflammation was associated with fewer complications related to portal hypertension and a lower risk of death.

Importantly, the study also highlighted that as portal hypertension worsens, the level of inflammation in the body increases. By reducing both portal pressure and systemic inflammation, beta-blockers may play a dual role in improving outcomes for patients with advanced liver disease.

This research could pave the way for more personalized treatment plans. With further validation in clinical trials, doctors may be able to better predict which patients will benefit most from beta-blocker therapy, allowing for tailored advice and care.

Understanding Chronic Liver Damage

Chronic liver damage can result from a variety of causes, including:

  • Alcohol abuse: Long-term excessive alcohol consumption can damage liver cells and lead to scarring.
  • Viral infections: Hepatitis B and C are common viral infections that can cause chronic liver disease.
  • Autoimmune disorders: Conditions where the immune system mistakenly attacks the liver.
  • Genetic disorders: Inherited conditions, such as hemochromatosis, can lead to liver damage.

Over time, ongoing damage to the liver causes fibrosis, or scarring, which eventually stiffens the liver. This makes it harder for blood to flow through, leading to portal hypertension. The increased pressure in the portal vein can cause serious complications:

  • Varices: Swollen veins in the esophagus or stomach that can rupture and cause life-threatening bleeding.
  • Ascites: Fluid accumulation in the abdomen, leading to discomfort and infections.
  • Hepatic encephalopathy: Cognitive dysfunction caused by the liver’s inability to remove toxins from the blood.

Beta-Blockers: More Than Blood Pressure Control

Beta-blockers have been a standard treatment for managing portal hypertension for many years. However, they are effective in reducing portal vein pressure in only 50% to 60% of patients. The new findings that beta-blockers also reduce systemic inflammation add an exciting dimension to their potential benefits.

By lowering inflammation, beta-blockers may help prevent complications of portal hypertension and improve survival rates in patients with advanced liver disease.

This dual effect—reducing both portal pressure and inflammation—makes beta-blockers a valuable option for managing cirrhosis and its complications.

The Path Forward

While this study highlights the potential of beta-blockers, more research is needed to confirm these findings in larger patient groups. The results offer hope for improving treatment strategies and outcomes for those with advanced liver disease.

If you or a loved one is dealing with chronic liver damage, it’s essential to consult with a healthcare provider. Treatment options may include lifestyle changes, medications like beta-blockers, and, in severe cases, liver transplant.

Each patient’s condition is unique, and medical professionals can provide guidance tailored to individual needs.

This study, led by Thomas Reiberger and published in Gut, underscores the importance of understanding how various treatments can address the complex challenges of liver disease. It also opens new doors for better managing this serious condition, potentially saving lives and improving quality of life for many patients.

If you care about liver health, please read studies about simple habit that could give you a healthy liver, and common diabetes drug that may reverse liver inflammation.

For more information about health, please see recent studies about simple blood test that could detect your risk of fatty liver disease, and results showing this green diet may strongly lower non-alcoholic fatty liver disease.

Copyright © 2025 Knowridge Science Report. All rights reserved.